Navigation Links
Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress
Date:7/8/2010

BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia. These presentations follow Pfizer's recent announcement about the creation of a new research unit focused on rare diseases, including hemophilia.

"We are very excited to present these data, which highlights the strength of our pipeline and our enduring commitment to provide recombinant products for the hemophilia community," says Brenda Cooperstone, M.D., vice president of clinical development and medical affairs for the Specialty Care Business Unit at Pfizer. "Our investigation of novel therapies for hemophilia treatment remains ongoing and we will continue to work closely with our partnersincluding the World Federation of Hemophiliato help improve hemophilia care worldwide."

Early Research with Factor Xa and VIIa

Pfizer will present the results of a pre-clinical study in mice indicating that recombinant factor Xa therapy may provide a unique way to bypass deficiencies in the intrinsic pathway. Additional results from a preclinical study in mice suggest that a recombinant factor VIIa molecule with increased activity and duration of action may have the potential to improve inhibitor outcomes.

Additional Hemophilia Research from Pfizer at WFH

  • New model of antibody-induced hemophilia A for the assessment of bypass therapies
  • An electronic documentation system in Haemophilia provides otherwise unavailable feedback for continuous quality control first results from the Haemoassist system
  • A prospective registry of European hemophilia B patients receiving BeneFIX (nonacog alfa, recombinant human factor IX) for usual use
  • Two-year interim results of a non-interventional trial to assess the safety and efficacy of treatment with recombinant factor IX
  • Safety and efficacy of B-domain-deleted recombinant FVIII final results of a 10 year pharmacovigilance study

Pfizer's Ongoing Commitment to the WFH and the Hemophilia Community

Pfizer will make a contribution to WFH at the meeting in support of the Twinning Program, which aims to increase the level of diagnosis and care for people with hemophilia by pairing emerging treatment centers and patient organizations with more established centers and organizations around the world. Wyeth, now part of Pfizer, has acted as the exclusive corporate sponsor of the world-renowned program since 2001, which currently has 32 Twinning partnerships worldwide. Historically, there have been 149 Twinnings. Pfizer will also host the annual reception for the Twinning Program.


'/>"/>

Contact: Gwen Fisher
Gwen.Fisher@Pfizer.com
484-865-5160
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. Pfizer joins open-access medicinal chemistry public-private collaboration
2. VIDEO from Medialink and National Fibromyalgia Association and Pfizer Inc.: The Science Behind Fibromyalgia
3. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
4. Arizona Myeloma Network presents Special Award to TGen president
5. ItsHot.com Presents Aesthetic Diamond Jewelry and Diamond Watches at Wholesale Prices
6. Morehead Presents Webinar on “Managing the Paradox of Employee Alignment and Engagement”
7. RockWest Technology Group Presents Campus Contactless Card Technology at NACCU
8. NextAid Presents BIDS BUILD HOPE Online Auction to Benefit Projects on the Ground in Africa on World AIDS Orphans Day
9. Morehead Presents Webinar on “Creating a High-Performing RN Workforce”
10. AllianceDiamonds.com Presents: Facebook Diamond Giveaway 2010
11. Aderans Research Presents at SID (Society of Investigative Dermatology)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
Breaking Medicine Technology: